HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BMRA

Biomerica, Inc.

Healthcare — Medical Devices

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. The company has strategic partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs for launching the inFoods platform in Canada. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

None
$2.20
$-0.06 (-2.60%)

Price History

52-Week Range
Sign in to add BMRA to a watchlist or set price alerts.

Fundamentals

Market Cap$5.56M
P/E Ratio (TTM)-
Forward P/E4.62
EPS (TTM)$-1.61
Dividend Yield-
Profit Margin-96.46%
Revenue Growth-11.80%
ROE-94.32%
Debt/Equity5.82
Recommendation None
Analyst Target-
Analysts-
Next Earnings -
Indexes -

Technical Indicators

RSI (14)33.8
Beta0.29
SMA 20-
SMA 40-
52-Week High$4.60
52-Week Low$1.73
50-Day Avg$2.14
200-Day Avg$2.38
Avg Volume18.4K
Volume2.9K

Performance Analysis

BEARISH

BMRA is flashing more cautionary signals — investors should monitor closely.

~ Trading at 16% of its 52-week range.
~ RSI at 33.8 is in neutral territory.
- Revenue declined 11.8% year-over-year.
- Operating at a loss with -96.5% margin.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:00 UTC

Back to Screener Export Report